

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	perampanel
Brand Name	Fycompa™
Dosage Form(s)	2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg tablets
Manufacturer	Eisai Limited
Submission Review	New Submission
Use Reviewed	Perampanel is indicated as adjunctive therapy in the management of partial-onset seizures, in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy.
Common Drug Review (CDR)	Yes. CDR recommended to list with criteria. Visit CDR website for more details: http://www.cadth.ca/media/cdr/complete/cdr_complete_Fycompa_October-21-13_e.pdf
Drug Benefit Council (DBC)	DBC met on January 20, 2014. DBC considered various inputs including the final review completed by the Common Drug Review (CDR) on October 17, 2013, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from one Patient, 5 Caregivers, and one Patient Group, Clinical Practice Reviews from one specialist, as well as a Budget Impact Assessment.
Drug Coverage Decision	<u>Limited Coverage Benefit.</u>
Date	August 15, 2014
Reason(s)	<p>Drug coverage decision is consistent with the DBC recommendation, but Limited Coverage criteria was adjusted to be consistent with lacosamide, another drug for the treatment of partial-onset seizures.</p> <ul style="list-style-type: none"> • Most doses of perampanel demonstrated advantage over placebo in reducing seizure frequency. Perampanel was similar to placebo with respect to frequency of adverse events. • Based on economic considerations and the submitted confidential product price, the drug offered value for money.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.